bpc-157 regulatory status fda not approved The Food and Drug Administration's committee on compounded drugs broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make. Follow the link In a major policy shift,
In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA's Overreach on Compounded Peptides RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion FDA may take an important step toward opening the peptide floodgates this week
Pay in 4 interest-free payments of $7.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

